SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-24-090303
Filing Date
2024-08-16
Accepted
2024-08-16 07:00:19
Documents
5
Period of Report
2024-09-16

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm2420696-3_def14a.htm DEF 14A 800974
2 GRAPHIC bc_netloss-4c.jpg GRAPHIC 54831
3 GRAPHIC bc_returntsr-4c.jpg GRAPHIC 60326
4 GRAPHIC px_24brainstormproxy1pg01-bw.jpg GRAPHIC 375968
5 GRAPHIC px_24brainstormproxy1pg02-4c.jpg GRAPHIC 181164
  Complete submission text file 0001104659-24-090303.txt   1696807
Mailing Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019
Business Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019 201-488-0460
BRAINSTORM CELL THERAPEUTICS INC. (Filer) CIK: 0001137883 (see all company filings)

IRS No.: 207273918 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36641 | Film No.: 241214102
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)